Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2009-12-10 Legal Proceedings Report
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Cyclopharm settles claim for US$1.8m 2 pages ?Kb
Legal Proceedings Report Classification · 90% confidence The document is a company announcement dated 11 December 2009 from Cyclopharm Limited. It discusses the settlement of a legal claim for US$1.8 million, updates on the FDA approval process for a new drug application, and strategic considerations for funding a Phase III clinical trial. The content focuses on legal settlement details, regulatory interactions, and strategic updates rather than presenting comprehensive financial statements or detailed financial performance data. The document length is 3950 characters, which is relatively short and more consistent with an announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, earnings release, or other detailed financial filing. The document primarily provides a legal and regulatory update along with strategic information, which aligns best with a Legal Proceedings Report (LTR).
2009-12-10 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, nature of the change, and other related information. This type of document is a formal notification of personal share transactions by a company director, which aligns with the definition of Director's Dealing filings. The document length is 3766 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. There is no indication that this is an annual report, audit report, or any other type of financial or regulatory filing. Therefore, the correct classification is Director's Dealing (DIRS).
2009-11-11 English
Cyclotron delivered to Macquarie University Hospital 2 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a company announcement dated November 2009 from Cyclopharm Limited, reporting the delivery and installation of a cyclotron at Macquarie University Hospital. It describes the company's business, the significance of the cyclotron installation, and future operational plans. There are no financial statements, regulatory filings, voting results, or management changes. The document is an operational update or milestone announcement rather than a formal financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general company announcement about a business development, which aligns best with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2009-11-08 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trades), and the value of the acquisition. There is no financial performance data, earnings information, or report content. This document is a report of personal share transactions by a company director, which fits the definition of Director's Dealing (DIRS). The document length is 2816 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is DIRS with high confidence.
2009-10-18 English
Response to an ASX Query - Director`s Interest Notices 4 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a letter from Cyclopharm Limited responding to a query from ASX Limited regarding late lodgement of Appendix 3Y forms, which are notices of changes in directors' interests in shares. The content focuses on compliance with listing rules related to director shareholding disclosures, specifically Listing Rules 3.19A and 3.19B, and the Corporations Act. It includes explanations for late filings, arrangements to ensure compliance, and steps to prevent future breaches. The document is not a financial report, earnings release, or management discussion, but rather a regulatory compliance communication about director share transactions and disclosure obligations. This fits the category of Regulatory Filings (RNS), as it is a regulatory announcement and compliance response that does not fit other specific categories like Director's Dealing (DIRS) because it is about the company's disclosure process and compliance rather than a direct report of insider trades themselves.
2009-10-13 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including acquisition dates, number of securities held before and after the change, and nature of the change (on-market trade). There is no financial performance data, earnings information, or report publication. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing' filings. The document length is short and focused solely on director share transactions, confirming it is not a broader report or announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2009-10-05 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.